ACE Inhibitor Titration Protocol
Start ACE inhibitors at low doses and uptitrate gradually every 1-2 weeks until reaching target doses proven effective in clinical trials, monitoring blood pressure, renal function, and potassium after each dose increase.
Starting Doses and Target Doses
The following evidence-based dosing regimens should guide your titration 1, 2:
| ACE Inhibitor | Starting Dose | Target Dose |
|---|---|---|
| Lisinopril | 2.5-5 mg once daily | 20-40 mg once daily |
| Enalapril | 2.5 mg twice daily | 10-20 mg twice daily |
| Ramipril | 1.25-2.5 mg once daily | 10 mg once daily |
| Captopril | 6.25 mg three times daily | 50 mg three times daily |
| Perindopril | 2 mg once daily | 8-16 mg once daily |
| Fosinopril | 5-10 mg once daily | 40 mg once daily |
| Quinapril | 5 mg twice daily | 20 mg twice daily |
| Trandolapril | 1 mg once daily | 4 mg once daily |
Titration Schedule
Increase the dose every 1-2 weeks if the lower dose is well tolerated 1, 3. The goal is to reach target doses used in major clinical trials, as these doses demonstrated mortality and morbidity benefits. Approximately 70-85% of patients can tolerate and achieve target doses with this approach 2.
Monitoring Requirements
Check the following parameters 1-2 weeks after initiation and after each dose increase 1, 3:
- Blood pressure (ensure systolic BP >80-90 mmHg)
- Serum creatinine
- Serum potassium
- Clinical symptoms
Once stable on target dose, monitor every 3-4 months 3, 4.
Pre-Titration Optimization
Before starting an ACE inhibitor 4, 5:
- Review diuretic dosing - reduce or withhold diuretics for 24 hours if patient is not volume overloaded to minimize first-dose hypotension
- Avoid excessive diuresis before treatment
- Consider starting the first dose in the evening when supine to minimize hypotensive effects
- Ensure adequate but not excessive volume status
When to Hold or Reduce Dose
Stop dose escalation or reduce dose if 1, 3:
- Creatinine increases >50% from baseline or >266 μmol/L (3 mg/dL)
- Potassium rises >5.5 mmol/L
- Systolic blood pressure drops <80 mmHg or patient develops symptomatic hypotension
- eGFR decreases >25% from baseline
Discontinue ACE inhibitor if 1, 3:
- Creatinine increases >100% (doubles) or reaches >310 μmol/L
- eGFR falls <20 mL/min/1.73m²
- Potassium exceeds 6.0 mmol/L despite dose reduction
- Angioedema occurs (absolute contraindication to all future ACE inhibitor use)
Special Populations
Heart Failure with Reduced Ejection Fraction
For HFrEF patients, target doses are critical - they were the doses that demonstrated mortality reduction in landmark trials 1, 2. Even if symptoms improve at lower doses, continue uptitration to target unless adverse effects occur. If target doses cannot be tolerated, intermediate doses provide benefit, though likely less than target doses 1, 6.
Post-Myocardial Infarction
Start within 24 hours if hemodynamically stable, particularly for anterior MI or reduced LVEF (≤0.40) 7. Use the same titration schedule but monitor more closely for hypotension in the acute setting.
Chronic Kidney Disease and Diabetes
A modest rise in creatinine (up to 30% increase) is expected and acceptable when starting ACE inhibitors in patients with diabetic kidney disease 8, 9. This does not indicate harm but rather hemodynamic changes from reduced intraglomerular pressure. Continue therapy unless creatinine rises exceed the thresholds above.
Common Pitfalls to Avoid
Under-dosing at discharge: Many patients receive only starting doses rather than being titrated to target doses, missing substantial clinical benefit 10, 11
Stopping potassium supplements prematurely: Avoid potassium-sparing diuretics during ACE inhibitor initiation, but don't automatically stop all potassium monitoring 1, 4
Concurrent NSAIDs: These block favorable effects and enhance adverse effects of ACE inhibitors - avoid them 4, 6
Mistaking cough for heart failure: ACE inhibitor cough is dry, persistent, with a "tickle" sensation, appears within the first months, and resolves within 1-2 weeks of stopping 12. Only discontinue if truly intolerable after excluding pulmonary congestion.
Combining with ARBs routinely: The combination of ACE inhibitor plus ARB increases risks of renal dysfunction and hyperkalemia without clear mortality benefit and is not recommended 1, 12
Practical Implementation
If intermediate doses are achieved but target doses cause adverse effects, maintain the intermediate dose - there are only small differences in efficacy between intermediate and high doses 1, 6. The most important principle is to use some dose of ACE inhibitor rather than none, while striving for target doses whenever tolerated.